Purpose. To determine the pharmacoeconomic impact of antimicrobial treatment of peptic ulcer disease (PUD) in a large urban jail.
INTRODUCTION
Peptic ulcer disease (PUD) is a common condition and is associated with substantial morbidity and mortality. Long-term histamine-2 (H-2) receptor antagonist therapy has been a mainstay of PUD management, with ranitidine being among were seronegative were offered either ranitidine or antacids, as well as gastroenterology consultation. Patients in the unlikely category were offered observation or antacids. All patients with persistent symptoms despite therapy were referred for gastroenterology consultation. After the initiation date of the new protocol, ranitidine, the only H-2 blocker in the formulary, was subject to automatic discontinuation by the pharmacy after 14 days. The responsible physician had the unrestricted right to override the discontinuation by completing a simple form and renewing the order.
Eradicative antimicrobial therapy consisted of tetracycline 500 mg qid, metronidazole 250 mg tid, and bismuth subsalicylate 2 tablets qid, along with ranitidine 300 mg at bedtime, all given orally for 14 days, a regimen with an expected efficacy of 90%. ~6 Tetracycline-intolerant patients received amoxicillin 500 mg orally qid instead.
Because the clinical activities and data acquisition described here were performed as part of the routine medical care and quality assurance process on Rikers Island, neither informed consent nor institutional review board oversight was sought.
DATA SOURCES
Records of monthly pharmacy expenditures for the medications listed above were available for all of 1995 and 1996; laboratory expenditures for H. pylori serologies were available from June 1995 through the end of 1996. Bismuth subsalicylate tablets were added to the Rikers Island formulary in October 1995.
Spending on bismuth subsalicylate prior to October 1995 and on H. pylori testing prior to June 1995 were assumed to be zero for the sake of the present analysis.
Usage of antacids constituted less than 5% of the overall expenditure, which did not change significantly after the intervention, and was thus not included in the analysis. Monthly Rikers Island census data were obtained from the New York City Department of Corrections. We calculated point prevalences of active ranitidine orders by counting active orders in the pharmacy database on a given day of each study month, at 30-day intervals, and dividing by the concurrent Rikers Island census. These statistics, as well as the duration of ranitidine therapy for each recipient, were available in the Rikers Island pharmacy database from August 1995 through June 1996.
STATISTICAL ANALYSIS
All statistical analyses were performed with SPSS for Windows version 6.1.2.
(SPSS Inc., Chicago, IL). Continuous variables were compared using the Student 
RESULTS
Monthly pharmacy expenditures for ranitidine, tetracycline, metronidazole, and bismuth subsalicylate and laboratory expenditures for H. pylori serologic testing are depicted in the Figure. Annualized total costs decreased by 40.2%, from $307,331 to $183,882 (P = .002). Annualized expenditures for ranitidine decreased by 52.2% (P < .001), while spending for antibiotics and serotesting increased by 6.2-fold (P < .001) and 9.7-fold (P < .001), respectively. The net overall cost reductions were not attributable to changes in patient census, which actually increased between 1995 and 1996.
In a separate analysis of practitioner ordering practices, active orders for ranitidine dropped sharply after the protocol start date. The mean point prevalence of active ranitidine orders decreased 35.5% after the intervention, from 9.82 to 6.33 orders per 1,000 inmates (P = .05). A simultaneous decline in the mean duration of ranitidine treatment from 55.3 to 24.1 days was also observed (P < .001).
DISCUSSION
The present study demonstrates significant cost savings as a result of the adoption of a modem PUD treatment strategy in a large correctional facility. There is now It should be pointed out that an analysis conducted in a correctional facility with a short average length of stay would tend to underestimate the true savings generated by a 14-day program of curative therapy compared to long-term, noncurative therapy, because an analysis in such a setting is more likely to capture the full cost of the 14-day therapy and only a fraction of the long-term alternative therapy costs. It is likely that savings in a community-based sample with longer follow-up would be significantly higher.
Certain limitations of the present study require mention. Although Rikers Island samples a substantial subset of the New York City population, findings in a jail population are not necessarily generalizable to the larger community.
There is no obvious reason, however, that the principles of PUD treatment or the efficacy thereof would be different for inmates. All usage of ranitidine, tetracycline, metronidazole, and bismuth subsalicylate on Rikers Island was assumed to be for the purpose of PUD care, and spending on bismuth subsalicylate and serotesting was assumed to be zero in the preintervention months, for which data were not available. These assumptions would tend to diminish the power of the analysis to detect a decrease in expenditures, leading to an underestimation of actual savings. Finally, the study was not designed to evaluate clinical outcomes. The study hypothesis and design were structured to measure the institutionwide budgetary impact of a patient care protocol and hence individual patient information was not collected or analyzed. While we are not aware of any obvious changes in PUD-related morbidity and mortality patterns in our facility since the intervention, major events may occur too infrequently to be detected in an analysis of this size. It is unlikely that non-pharmacy-based expenditures have increased to offset our savings, since other studies have convincingly demonstrated a decrease in morbid events and PUD-related health care costs in patients who were treated with eradicative antimicrobial therapy versus H-2 blockers. 1~
It is quite possible, therefore, that the savings observed in this study represent just the "tip of the iceberg" when other sources of long-term savings are considered.
The association of H. pylori with PUD represents an important advance in medical science. The optimal diagnostic techniques and treatment modalities for PUD associated with H. pylori remain subjects of debate and controversy. We have opted to employ a semiempiric approach, which expands the role of eradicative antimicrobial therapy and minimizes the long-term usage of ranitidine. While modernizing our treatment of PUD in a large urban jail, we have generated significant, sustained cost savings within our pharmacy budget. Contrary to popular impression, advances in medical science, in certain instances, may result in improved care at reduced cost.
ADDENDUM
As of January 1, 1998, after the preparation of this manuscript, the relationship between New York City and Montefiore Medical Center to provide care to the inmates of Rikers Island Correctional Facility was dissolved. Statements in this paper that reflect principles and practice of care within the facility may no longer pertain.
